Join Richmond Pharmacology next month for the DIA Cardiovascular Safety and State-of-the-art Development Issues meeting taking place 17 to 18 April 2012 in Washington.The meeting will address present issues surrounding Type 2 Diabetes Mellitus Medications, QT, Benefit/Risk Assessment, Arrhythmias, Thrombosis, and Cardiotoxicity during a series of debate-style presentations from international industry, academic, and regulatory speakers.Dr Jorg Taubel's current research is concerned with the cardiovascular effects of meals, insulin and C-peptide in Caucasian and Japanese populations. He will be presenting some of his most recent findings on Day 2 (18 Apr 2012), covering the following topics of discussion:Session 6, CV Safety Track at 10h30:

  • Moxifloxacin effect on the QTc interval in fed and fasted states in Thorough QT studies

Session 4, Diabetes Track at 11h00:

  • Insulin does not prolong the QT interval in thorough QT studies performed in healthy volunteers

For further information on Richmond Pharmacology�s specialist Cardiovascular Safety expertise or to request a copy of our latest TQT publication, contact a member of our Business Development team today. Alternatively we hope to see you in the US next month!

Latest news

Richmond Pharmacology appoints Sandra Johnson as Director of Commercial Project Management

September 19, 2022
We are delighted to announce that Sandra Johnson will join Richmond Pharmacology as its new Director for Commercial Project Management
Read more

How telemonitoring can revolutionise the way we treat patients – Tom York

November 17, 2022
Richmond Pharmacology always searches for the most innovative processes to improve clinical trials and the patients’ experiences and treatments.
Read more

Events

JPW2022 (Japan Basic and Clinical Pharmacology Week 2022)

30 November – 3 December 2022
This event will be the 96th Annual Meeting of the Japanese Pharmacological Society and the 43rd Annual Meeting of the Japanese Society of Clinical Pharmacology. 
View event